NEW YORK — Robert Bosch Venture Capital (RBVC) said on Monday that it has invested in Variantyx as part of the genomic testing company's expanded $26 million Series C financing round. Peregrine Ventures has also joined the round, according to Variantyx.
In March, Variantyx said it raised $20 million in the Series C round, which was led by GHS Fund (Quark Venture LP and GF Securities) and included new investor IBM Ventures and current investors Pitango Venture Capital, New Era Capital Partners, and 20/20 HealthCare Partners.
Boston-based Variantyx uses a proprietary whole-genome sequencing-based testing method for diagnosing rare inherited and neurological disorders but said earlier this year that it is expanding into oncology and prenatal testing.
As part of the investment from RBVC, the corporate venture capital arm of German engineering firm Bosch Group, Variantyx will team up with Robert-Bosch Hospital to provide clinicians with diagnostic tests and personalized treatment recommendations for cancer patients using its proprietary software.
"Together, Variantyx and Bosch are eyeing to bring new research, diagnostics, and precision medicine to oncology patients and clinicians," Ingo Ramesohl, managing director of RBVC, said in a statement.